The original disclosure in Japanese was released on January 30, 2019 at 15:30 (GMT+9)

Consolidated Financial Statements for the Third Quarter Ended December 31, 2018
FY2019 (April 1, 2018 - March 31, 2019) [UNAUDITED]

Company name: Takara Holdings Inc.
Stock exchange listings: Tokyo Stock Exchange (1st section)
Code number: 2531
URL: https://www.takara.co.jp/
Company representative: Mutsumi Kimura, President
Contact: Takuya Kakemi, General Manager of Investor Relations Dept.
TEL : (075)241-5124

Quarterly statement filing date (as planned): February 8, 2019

Notes:
1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.

1. Results for the nine months ended December 31, 2018 (April 1, 2018 - December 31, 2018)

(1) Consolidated Operating results

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Nine months ended December 31, 2018		Nine months ended December 31, 2017	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	210,622	3.1	204,266	18.6
Operating income (loss)	15,015	10.4	13,604	6.8
Ordinary income (loss)	15,420	10.3	13,984	4.3
Net income (loss) attributable to owners of the parent	8,952	(13.9)	10,396	17.1
Net income (loss) per share (Yen)	44.85		51.74	
Fully diluted net income per share (Yen)	-		-	
Note: Comprehensive income (loss)	6,807	(54.2)	14,849	852.7

(2) Consolidated Financial position

	As of December 31, 2018	As of March 31, 2018
	(Millions of yen)	(Millions of yen)
Total assets	290,503	284,281
Net assets	179,520	176,217
Equity ratio (%)	50.9	51.0
(Reference) Equity	147,891	145,111

2. Dividends

	Dividend per share (Yen)		
	Year ended March 31, 2018	Year ending March 31, 2019	Year ending March 31, 2019 (Forecast)
First quarter end	-	-	
Second quarter end	-	-	
Third quarter end	-	-	
Year end	16.00		18.00
Annual	16.00		18.00

Note: Correction of dividend forecast from the most recent dividend forecast : No

3. Forecast for the year ending March 31, 2019 (April 1, 2018 - March 31, 2019)

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Year ending March 31, 2019	
	(Millions of yen)	(%)
Net sales	280,000	4.4
Operating income (loss)	17,300	10.8
Ordinary income (loss)	17,900	11.3
Net income (loss) attributable to owners of the parent	10,000	(9.3)
Net income per share (Yen)	50.09	

Note: Correction of financial forecast from the most recent financial forecast : No

4. Others

(1) Material changes in subsidiaries during this period
(Changes in specified subsidiaries that caused a change in the scope of consolidation) : No

(2) Accounting procedures specific to quarterly consolidated financial statements : No

(3) Changes in accounting policies, accounting estimates and retrospective restatement

1) Changes based on revisions of accounting standard : No

2) Changes other than ones based on revisions of accounting standard : No

3) Changes in accounting estimates : No

4) Restatement : No

(4) Number of outstanding shares (common stock)

1) Number of outstanding shares at the end of each period (Treasury stocks are included)

As of December 31, 2018 : 201,699,743

As of March 31, 2018 : 201,699,743

2) Number of treasury stocks at the end of each period

As of December 31 30, 2018 : 2,069,706

As of March 31, 2018 : 2,069,224

3) Average number of outstanding shares in each period

Nine months ended December 31, 2018 : 199,630,283

Nine months ended December 31, 2017 : 200,960,374

Contents of the attached document

1. Qualitative Information for the Nine Months Ended December 31, 2018……..... 2
(1) Consolidated Financial Results……...… 2
(2) Consolidated Financial Position ……..……... 3
(3) Qualitative Information Regarding Consolidated Forecasts……..…. 3
2. Consolidated Quarterly Financial Statements and Important Notes…….. 5
(1) Consolidated Quarterly Balance Sheets…….. 5
(2) Consolidated Quarterly Statements of Income and Consolidated Quarterly Statements of Comprehensive Income …… 7
Consolidated Quarterly Statements of Income (For the Nine Months Ended December 31, 2018 and 2017) …… 7
Consolidated Quarterly Statements of Comprehensive Income (For the Nine Months Ended December 31, 2018 and 2017) ……..... 8
(3) Notes on Consolidated Quarterly Financial Statements …… 9
(Notes on Premise of Going Concern) …… 9
(Notes on Material Changes in Shareholders' Equity) …… 9
(Additional Information) ……. 9
(Segment Information) …… 9

○Supplement for the Consolidated Quarterly Financial Statements

1. Qualitative Information for the Nine Months Ended December 31, 2018

(1) Consolidated Financial Results

In the nine months ended December 31, 2018, although personal spending was weak, the Japanese economy overall maintained a moderate recovery backed by improvements in corporate earnings and the hiring environment. On the other hand, overseas, while economic expansion was expected to continue centered on Europe and the U.S., there were risk factors such as trade friction originating in the U.S. and tension in the Middle East, meaning the global economic outlook remained uncertain.

In these economic circumstances, under the Takara Group Medium-Term Management Plan FY2020, which is the last step towards achieving its long-term Takara Group Vision 2020, the Company is aiming to build up a great number of fields in which it can beat competitors and establish a balanced business foundation able to grow revenues significantly, no matter what environmental changes occur, by further increasing the overseas sales ratio together with having a full product line-up and many products with a competitive edge, both in Japan and overseas.

As a result, in the nine months ended December 31, 2018, net sales were up 3.1% year on year to ¥210,622 million. Gross profit rose 3.9% year on year to ¥82,915 million. Operating income increased by 10.4% year on year to ¥15,015 million while ordinary income rose 10.3% year on year to ¥15,420 million. Net income attributable to owners of the parent decreased by 13.9% year on year to ¥8,952 million.

Results by business segment were as follows.

[Takara Shuzo]

For alcoholic beverages in the nine months ended December 31, 2018, while sales of shochu and sake decreased, sales of light alcohol refreshers, where *Takara Shochu High Ball* remained robust, rose, and sales of alcoholic beverages overall increased. In the Seasonings Business, sales were down due to decreased sales of mirin and other products. Sales of raw alcohol and other products were up, mainly as sales of industrial alcohol remained favorable.

As a result, net sales for the Takara Shuzo Group rose 1.0% year on year to ¥119,001 million. Cost of sales increased by 1.3% year on year to ¥70,919 million. Consequently, gross profit rose 0.6% year on year to ¥48,081 million. SG&A expenses were up by 0.7% year on year to ¥41,397 million, due to increases in transportation and promotion expenses and other expenses. Accordingly, the Takara Shuzo Group recorded operating income down 0.2% year on year to ¥6,683 million.

[Takara Shuzo International Group]

In the nine months ended December 31, 2018, sales in the Japanese food wholesale business in overseas markets increased with robust sales at FOODEX S.A.S. (France), Mutual Trading Co., Inc. (U.S.), and other companies. As a result, net sales for the Takara Shuzo International Group increased by 10.7% year on year to ¥56,843 million. Cost of sales increased by 11.1% year on year to ¥40,196 million. Consequently, gross profit rose by 9.6% year on year to ¥16,647 million. SG&A expenses were up by 11.9% year on year to ¥13,416 million due mainly to increases in personnel and transportation expenses. Accordingly, the Takara Shuzo International Group recorded operating income up 0.8% to ¥3,230 million.

[Takara Bio Group]

Net sales for the nine months ended December 31, 2018 were up by 14.3% year on year to ¥25,888 million, mainly due to increased sales of mainstay research reagents and the receipt of consideration in relation to a domestic co-development and exclusive sales agreement for NY-ESO-1 siTCR® gene therapy product and CD19 CAR gene therapy product. Cost of sales increased by 10.8% year on year to ¥10,947 million due to the increase in net sales. As a result, gross profit rose by 17.0% year on year to ¥14,940 million. SG&A expenses increased by 3.1% year on year to ¥11,507 million due to an increase in personnel expenses and other factors. Accordingly, operating income increased by 113.4% year on year to ¥3,432 million.

[Other]

Net sales of the Other segment for the nine months ended December 31, 2018 declined by 12.0% year on year to ¥25,593 million, as TAKARA CHOU UN Co., Ltd. was excluded from the scope of consolidation during the previous fiscal year accompanying the sale of shares in that company. Cost of sales declined by 11.3% year on year to ¥21,621 million. Consequently, gross profit decreased by 15.8% year on year to ¥3,971 million. SG&A expenses fell by 10.7% year on year to ¥2,320 million. As a result, operating income decreased by 22.0% year on year to ¥1,651 million.

Breakdown of sales results by product category

Segment	Equivalent Period of Previous Fiscal Year (From April 1, 2017, to December 31, 2017)	Period under Review (from April 1, 2018, to December 31, 2018)	YoY Comparison
Product category	Amount (Millions of yen)	Amount (Millions of yen)	(%)
Takara Shuzo			
Shochu	42,608	41,186	96.7
Sake	18,302	17,524	95.7
Light-alcohol refreshers	26,602	29,742	111.8
Other alcoholic beverages	5,133	5,051	98.4
Alcoholic beverages total	92,647	93,505	100.9
Hon Mirin	11,304	11,032	97.6
Other seasonings	7,851	7,779	99.1
Seasonings total	19,156	18,811	98.2
Raw alcohol, etc	6,041	6,683	110.6
Total	117,845	119,001	101.0
Takara Shuzo International Group			
Overseas Alcoholic Beverages Business	7,424	7,616	102.6
Japanese Food Wholesales Business in overseas markets	45,231	50,591	111.9
Other	33	48	145.2
Elimination of intraGroup transaction on consolidation	(1,324)	(1,413)	–
Total	51,364	56,843	110.7
Takara Bio Group	22,646	25,888	114.3
Reported segment total	191,856	201,732	105.1
Other	29,090	25,593	88.0
Segment total	220,946	227,326	102.9
Sales not allocated to business segments and intersegment transactions	(16,680)	(16,703)	–
Total	204,266	210,622	103.1

Notes: Amounts include alcohol tax but do not include consumption tax.

(2) Consolidated Financial Position

As of December 31, 2018, current assets were ¥181,694 million, an increase of ¥10,626 million compared with that at the end of the previous fiscal year. This was primarily due to increases in cash and deposits of ¥1,239 million, notes and accounts receivable-trade of ¥12,550 million, merchandise and finished goods of ¥3,406 million, and other current assets of ¥1,313 million, and a decrease in securities of ¥8,622 million.

Noncurrent assets were ¥108,808 million, a decrease of ¥4,405 million compared with that at the end of the previous fiscal year. This was primarily due to decreases in intangible fixed assets of ¥1,429 million and investment securities of ¥3,745 million.

As a result, total assets were ¥290,503 million, an increase of ¥6,221 million compared with that at the end of the previous fiscal year.

As of December 31, 2018, current liabilities were ¥61,785 million, an increase of ¥9,073 million compared with that at the end of the previous fiscal year. This was primarily due to increases in notes and accounts payable-trade of ¥2,077 million, short-term loans payable of ¥4,726 million, mainly due to transfers from noncurrent liabilities, and accrued alcohol tax of ¥3,375 million. There was also a decrease of ¥1,057 million in income taxes payable and other current liabilities.

Noncurrent liabilities were ¥49,197 million, a decrease of ¥6,154 million compared with that at the end of the previous fiscal year. This was primarily due to decreases in long-term loans payable of ¥5,170 million and other noncurrent liabilities of ¥1,057 million due mainly to a decrease in deferred tax liabilities.

As a result, total liabilities were ¥110,982 million, an increase of ¥2,918 million compared with that at the end of the previous fiscal year.

As of December 31, 2018, total net assets were ¥179,520 million, an increase of ¥3,303 million compared with that at the end of the previous fiscal year. This was primarily due to an increase in retained earnings of ¥5,758 million and a decrease in valuation difference on available-for-sale securities of ¥2,641 million.

As a result, the equity ratio totaled 50.9%, compared with 51.0% at the end of the previous fiscal year.

(3) Qualitative Information Regarding Consolidated Forecasts

The Group's consolidated business results in the nine months ended December 31, 2018 progressed largely in line with the

consolidated business results forecast released on November 6, 2018.

On January 30, 2019 Takara Bio Inc. (First Section of the TSE, code 4974), which is a consolidated subsidiary of the Company, released Notice Regarding Forecast Revisions of Financial Results and Dividend (Dividend Increase). However, the Group's consolidated business results forecast will not be revised as the effect on the consolidated business results is negligible.

2. Consolidated Quarterly Financial Statements and Important Notes

(1) Consolidated Quarterly Balance Sheets

(Millions of Yen)

	As of Mar. 31, 2018	As of Dec. 31, 2018
Assets		
Current assets		
Cash and deposits	47,754	48,994
Notes and accounts receivable-trade	57,889	70,400
Securities	19,721	11,099
Merchandise and finished goods	37,979	41,386
Work in process	997	1,392
Raw materials and supplies	3,932	4,311
Other	3,122	4,435
Allowance for doubtful accounts	(329)	(366)
Total current assets	171,067	181,694
Noncurrent assets		
Property, plant and equipment	57,485	57,597
Intangible assets		
Goodwill	13,765	13,022
Other	8,504	7,818
Total intangible assets	22,269	20,840
Investments and other assets		
Investment securities	28,607	24,862
Other	4,928	5,576
Allowance for doubtful accounts	(77)	(68)
Total investments and other assets	33,458	30,371
Total noncurrent assets	113,213	108,808
Total assets	284,281	290,503

(Millions of Yen)

	As of Mar. 31, 2018	As of Dec. 31, 2018
Liabilities		
Current liabilities		
Notes and accounts payable-trade	16,544	18,621
Short-term loans payable	5,221	9,947
Current portion of bonds		
Accrued alcohol tax	9,278	12,654
Accrued expenses	5,639	5,775
Income taxes payable	3,126	2,069
Provision for bonuses	2,286	1,570
Provision for sales promotion expenses	1,853	2,206
Other provision	225	250
Other	8,535	8,689
Total current liabilities	52,712	61,785
Noncurrent liabilities		
Bonds payable	25,000	25,000
Long-term loans payable	10,620	5,449
Net defined benefit liability	8,759	8,794
Long-term deposits received	5,312	5,351
Other	5,659	4,601
Total noncurrent liabilities	55,352	49,197
Total liabilities	108,064	110,982
Net assets		
Shareholders' equity		
Capital stock	13,226	13,226
Capital surplus	2,219	2,262
Retained earnings	117,571	123,329
Treasury stock	(1,367)	(1,368)
Total shareholders' equity	131,649	137,450
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	11,520	8,878
Deferred gains or losses on hedges	(120)	100
Foreign currency translation adjustment	2,645	2,054
Remeasurements of defined benefit plans	(583)	(592)
Total accumulated other comprehensive income	13,461	10,440
Noncontrolling interests	31,106	31,629
Total net assets	176,217	179,520
Total liabilities and net assets	284,281	290,503

(2) Consolidated Quarterly Statements of Income and Consolidated Quarterly Statements of Comprehensive Income

(Consolidated Statements of Income)
(For the Nine Months Ended December 31, 2018 and 2017)

(Millions of Yen)

	FY2018 (Apr. 1, 2017 – Dec. 31, 2017)	FY2019 (Apr. 1, 2018 – Dec. 31, 2018)
Net sales	204,266	210,622
Cost of sales	124,486	127,706
Gross profit	79,779	82,915
Selling, general and administrative expenses	66,175	67,900
Operating income	13,604	15,015
Non-operating income		
Dividends income	497	553
Other	644	512
Total non-operating income	1,141	1,065
Non-operating expenses		
Interest expenses	463	276
Other	297	384
Total non-operating expenses	761	661
Ordinary income	13,984	15,420
Extraordinary income		
Insurance income	—	71
Gain on sales of stocks of subsidiaries and affiliates	3,312	—
Other	174	9
Total extraordinary income	3,486	81
Extraordinary loss		
Impairment loss	—	696
Other	106	378
Total extraordinary losses	106	1,075
Income before income taxes and minority interests	17,364	14,426
Income taxes-current	5,824	4,627
Income taxes-deferred	342	(310)
Total income taxes	6,167	4,316
Net income	11,197	10,110
Net income attributable to the noncontrolling interest	800	1,157
Net income attributable to owners of the parent	10,396	8,952

(Consolidated Quarterly Statements of Comprehensive Income)
(For the Nine Months Ended December 31, 2018 and 2017)

(Millions of Yen)

	FY2018 (Apr. 1, 2017 – Dec. 31, 2017)	FY2018 (Apr. 1, 2018 – Dec. 31, 2018)
Net income	11,197	10,110
Other comprehensive income		
Valuation difference on available-for-sale securities	2,872	(2,641)
Deferred gains or losses on hedges	201	214
Foreign currency translation adjustment	541	(875)
Remeasurements of defined benefit plans	36	(0)
Total other comprehensive income	3,651	(3,302)
Comprehensive income	14,849	6,807
(Comprehensive income attributable to)		
Comprehensive income attributable to owners of the parent	14,150	5,931
Comprehensive income attributable to noncontrolling interest	698	875

(3) Notes on Consolidated Quarterly Financial Statements

(Notes on Premise of Going Concern)

No items to report.

(Notes on Material Changes in Shareholders' Equity)

No items to report.

(Additional Information)

(Adoption of the Partial Amendments to Accounting Standard for Tax Effect Accounting, etc.)

Following the adoption of the Partial Amendments to Accounting Standard for Tax Effect Accounting (ASBJ Statement No. 28, February 16, 2018) and other standards from the beginning of the first quarter of the fiscal year under review, Deferred Tax Assets is classified as Investments and Other Assets and Deferred Tax Liabilities is classified as Noncurrent Liabilities.

(Segment Information)

I Equivalent Period of Previous Fiscal Year (From April 1, 2017, to December 31, 2017)

1. Net Sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal				
Net sales								
External customers	117,566	51,123	22,112	190,803	13,455	204,258	7	204,266
Intersegment	278	241	533	1,053	15,634	16,688	(16,688)	–
Total	117,845	51,364	22,646	191,856	29,090	220,946	(16,680)	204,266
Segment income (loss)	6,698	3,206	1,608	11,513	2,115	13,629	(25)	13,604

Notes: 1. Other includes business segments that are not part of reported segments, such as the Company's real estate rental business and the transportation business of domestic Group companies among others.

2. Details of adjustment amounts are as follows.

(1) Net sales to external customers are income from business contracting recorded at the Company.

(2) Segment income (loss) comprises ¥60 million of intersegment eliminations and ¥-86 million in income of the Company not allocated to business segments.

3. Segment income (loss) has been adjusted to the operating income of consolidated quarterly statements of income.

2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

(Significant Changes in the Amount of Goodwill)

In the Takara Bio Group segment, goodwill was recorded due to the acquisition of shares in WaferGen Bio-systems, Inc. and Rubicon Genomics, Inc. by Takara Bio Inc.'s wholly owned subsidiary Takara Bio USA Holdings Inc. The increase in goodwill due to this event in the nine months ended December 31, 2018 was ¥7,713 million. Note that as the allocation of the acquisition cost has not been completed, this is a tentatively calculated amount.

II Period under Review (From April 1, 2018, to December 31, 2018)

1. Net Sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal				
Net sales								
External customers	118,520	56,625	25,480	200,626	9,996	210,622	0	210,622
Intersegment	481	217	407	1,106	15,597	16,703	△16,703	−
Total	119,001	56,843	25,888	201,732	25,593	227,326	△16,703	210,622
Segment income	6,683	3,230	3,432	13,346	1,651	14,997	18	15,015

Notes: 1. Other includes business segments that are not part of reported segments, such as the Company's real estate rental business and the transportation business of domestic Group companies among others.

2. Details of adjustment amounts are as follows.

(1) Net sales to external customers are income from business contracting recorded at the Company.

(2) Segment income (loss) comprises ¥55 million of intersegment eliminations and -¥37 million in losses of the Company not allocated to business segments.

3. Segment income (loss) has been adjusted to the operating income of consolidated quarterly statements of income

2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

(Significant Impairment Losses Concerning Noncurrent Asset)

Impairment losses relating to business assets which are expected to be idle and assets relating to a planned business transfer have been recorded in the Takara Bio Group segment as extraordinary loss.

The amount of impairment losses recorded was ¥696 million in the nine months ended December 31, 2018.

平成31年3月期
第3四半期決算短信補足資料

Supplement for the Consolidated Financial Statements
for the Third Quarter Ended December 31, 2018

1. 宝ホールディングス(連結)
   Takara Holdings Inc. -Consolidated-
   グループ別要約損益計算書
   Consolidated Statements of Income by Business Group (Summary)

2. 宝酒造
   Takara Shuzo Co.,Ltd.
   要約損益計算書
   Statements of Income (Summary)

3. 宝酒造インターナショナルグループ
   Takara Shuzo International Group
   要約損益計算書
   Statements of Income (Summary)

4. タカラバイオグループ
   Takara Bio Group
   要約損益計算書
   Statements of Income (Summary)

5. 6年間の財務サマリー(グループ別)
   Six-Year Financial Summary by Business Group

6. 平成31年3月期第3四半期　参考資料
   Reference Data for the Third Quarter Ended December 31, 2018

宝ホールディングス株式会社
TAKARA HOLDINGS INC.

IR部 Investor Relations Dept.
TEL 075(241)5124
FAX 075(241)5194
E-Mail ir@takara.co.jp

将来見通しに関する注意事項

この資料中の当社および当社グループの現在の計画、見通し、戦略、確信などのうち、歴史的事実でないものは、将来の業績に関する見通しであり、これらは現時点において入手可能な情報から得られた当社経営陣の判断に基づくものですが、重大なリスクや不確実性を含んでいる情報から得られた多くの仮定および考えに基づきなされたものであります。実際の業績は、さまざまな要素によりこれら予測とは大きく異なる結果となり得ることをご承知おきください。

実際の業績に影響を与える要素には、経済情勢、特に消費動向、為替レートの変動、法律・行政制度の変化、競合会社の価格・製品戦略による圧力、当社の既存製品および新製品の販売力の低下、生産中断、当社の知的所有権に対する侵害、急速な技術革新、重大な訴訟における不利な判決等がありますが、業績に影響を与える要素はこれらに限定されるものではありません。

Forward-Looking Statements

Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors.

Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of the Company's intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

宝ホールディングス株式会社　IR部

Takara Holdings Inc. Investor Relations Dept.

TEL 075(241)5124　FAX 075(241)5194

E-Mail ir@takara.co.jp

1. 宝ホールディングス(連結) Takara Holdings Inc. -Consolidated-

グループ別要約損益計算書 Consolidated Statements of Income by Business Group (Summary)

→[参考:通期 Reference:Full year]

(百万円 Millions of Yen)

	平成30年3月期 第3四半期累計	平成31年3月期 第3四半期累計 Apr. 1, 2018 - Dec. 31, 2018			平成30年3月期 通期	平成31年3月期 通期 Apr. 1, 2018 - Mar. 31, 2019		
	実績(a) FY2018(1Q-3Q) Actual (a)	実績(b) FY2019(1Q-3Q) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)	実績(c) FY2018 Actual (c)	11/6予想(d) FY2019 Forecast announced Nov. 2018 (d)	増減(d-c) Change (d-c)	比(d/c) YOY% (d/c)
宝酒造 Takara Shuzo Group	117,845	119,001	1,155	101.0%	149,839	154,000	4,160	102.8%
宝酒造インターナショナルグループ Takara Shuzo International Group	51,364	56,843	5,478	110.7%	70,717	78,000	7,282	110.3%
タカラバイオ グループ Takara Bio Group	22,646	25,888	3,242	114.3%	32,312	＊ 35,800	3,487	110.8%
その他 Other	29,090	25,593	△ 3,496	88.0%	36,412	33,000	△ 3,412	90.6%
調整額 Adjustment	△ 16,680	△ 16,703	△ 23	－	△ 21,140	△ 20,800	340	－
売上高 Net sales	204,266	210,622	6,356	103.1%	268,142	280,000	11,857	104.4%
売上原価 Cost of sales	124,486	127,706	3,219	102.6%	163,529	169,900	6,370	103.9%
売上総利益 Gross profit	79,779	82,915	3,136	103.9%	104,612	110,100	5,487	105.2%
運送費、保管料 Transportation and storage	7,373	7,823	450	106.1%	9,665	10,500	834	108.6%
広告宣伝費 Advertising	2,487	2,289	△ 198	92.0%	3,073	2,900	△ 173	94.3%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	24,840	25,131	291	101.2%	33,688	34,300	611	101.8%
研究開発費 Research and development	3,726	3,444	△ 281	92.4%	5,063	5,000	△ 63	98.8%
管理費、その他 Other, net	27,747	29,210	1,463	105.3%	37,508	40,100	2,591	106.9%
販売費及び一般管理費 SG&A expenses	66,175	67,900	1,724	102.6%	88,999	92,800	3,800	104.3%
宝酒造 Takara Shuzo Group	6,698	6,683	△ 15	99.8%	5,569	6,100	530	109.5%
宝酒造インターナショナルグループ Takara Shuzo International Group	3,206	3,230	24	100.8%	4,393	4,900	506	111.5%
タカラバイオ グループ Takara Bio Group	1,608	3,432	1,823	213.4%	3,555	＊ 5,000	1,444	140.6%
その他 Other	2,115	1,651	△ 464	78.0%	2,318	2,000	△ 318	86.3%
調整額 Adjustment	△ 25	18	44	－	△ 224	△ 700	△ 475	－
営業利益(△:損失) Operating income(Δ:loss)	13,604	15,015	1,411	110.4%	15,612	17,300	1,687	110.8%
受取利息・配当金 Interest and Dividends income	614	691	77	112.5%	700	700	△ 0	99.9%
その他営業外収益 Other, net	527	373	△ 153	70.8%	707	600	△ 107	84.8%
営業外収益 Non-operating income	1,141	1,065	△ 76	93.3%	1,408	1,300	△ 108	92.3%
支払利息 Interest and discounts expenses	463	276	△ 187	59.6%	568	300	△ 268	52.7%
その他営業外費用 Other, net	297	384	86	129.2%	367	400	32	108.9%
営業外費用 Non-operating expenses	761	661	△ 100	86.8%	936	700	△ 236	74.8%
経常利益(△:損失) Ordinary income(Δ:loss)	13,984	15,420	1,435	110.3%	16,084	17,900	1,815	111.3%
特別利益 Extraordinary income	3,486	81	△ 3,405	2.3%	3,499	250	△ 3,249	7.1%
特別損失 Extraordinary loss	106	1,075	968	－	679	1,050	370	154.5%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	17,364	14,426	△ 2,938	83.1%	18,903	17,100	△ 1,803	90.5%
法人税、住民税及び事業税 Current income taxes	5,824	4,627	△ 1,197	79.4%	6,859	5,300	△ 1,074	83.1%
法人税等調整額 Deferred income taxes	342	△ 310	△ 653	－	△ 484			
四半期純利益(△:損失) Net income(Δ:loss)	11,197	10,110	△ 1,087	90.3%	12,528	11,800	△ 728	94.2%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	800	1,157	356	144.6%	1,499	1,800	300	120.0%
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	10,396	8,952	△ 1,444	86.1%	11,029	10,000	△ 1,029	90.7%
設備投資額(有形・無形) Capital expenditures	3,738	5,156	1,417	137.9%	6,414	14,900	8,485	232.3%
減価償却費(有形・無形) Depreciation and Amortization	4,767	4,813	46	101.0%	6,430	6,600	169	102.6%
のれん償却額 Amortization of goodwill	625	646	21	103.4%	843	870	26	103.2%

＊ タカラバイオグループは、平成31年3月期通期業績予想を1/30に修正しております。(p4参照)
Takara Bio Group revised FY2019 forecasts on January 30, 2019. (c.f. p4.)

営業外収益 Non-operating income	受取利息138、受取配当金553 など Interest income 138, Dividends income 553, etc.
営業外費用 Non-operating expenses	支払利息150、社債利息125 など Interest expense 150, Interest on bonds 125, etc.
特別利益 Extraordinary income	(前期:関係会社株式売却益3,312 など) (FY2018(3Q): Gain on sales of subsidiaries and affiliates' stocks 3,312 etc.)
特別損失 Extraordinary loss	固定資産除売却損128、減損損失696、災害による損失205 など Loss on sales and retirement of noncurrent assets 128, Impairment loss 696, Loss on disaster 205, etc.

2. 宝酒造 :Takara Shuzo Co., Ltd.

要約損益計算書 Statements of Income (Summary)

→[参考:通期 Reference:Full year]

(百万円 Millions of Yen)

	平成30年3月期 第3四半期累計	平成31年3月期 第3四半期累計 Apr. 1, 2018 - Dec. 31, 2018			平成30年3月期 通期	平成31年3月期 通期 Apr. 1, 2018 - Mar. 31, 2019		
	実績(a) FY2018(1Q-3Q) Actual (a)	実績(b) FY2019(1Q-3Q) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)	実績(c) FY2018 Actual (c)	11/6予想(d) FY2019 Forecast announced Nov. 2018 (d)	増減(d-c) Change (d-c)	比(d/c) YOY% (d/c)
焼酎 Shochu	42,608	41,186	△ 1,421	96.7%	55,034	53,800	△ 1,234	97.8%
清酒 Sake	18,302	17,524	△ 778	95.7%	22,222	22,700	477	102.2%
ソフトアルコール飲料 Light-alcohol refreshers	26,602	29,742	3,140	111.8%	34,267	39,300	5,032	114.7%
その他酒類 Other liquors	5,133	5,051	△ 82	98.4%	6,639	6,300	△ 339	94.9%
本みりん Hon Mirin	11,304	11,032	△ 272	97.6%	14,063	13,500	△ 563	96.0%
その他調味料 Other seasonings	7,851	7,779	△ 72	99.1%	9,760	9,800	39	100.4%
原料用アルコール等 Raw alcohol	6,041	6,683	642	110.6%	7,852	8,600	747	109.5%
売上高 Net sales	117,845	119,001	1,155	101.0%	149,839	154,000	4,160	102.8%
売上原価 Cost of sales	70,038	70,919	881	101.3%	89,681	92,300	2,618	102.9%
売上総利益 Gross profit	47,806	48,081	274	100.6%	60,158	61,700	1,541	102.6%
運送費、保管料 Transportation and storage	5,659	5,867	208	103.7%	7,251	7,600	348	104.8%
広告宣伝費 Advertising	2,150	1,981	△ 168	92.2%	2,601	2,500	△ 101	96.1%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	23,864	24,148	284	101.2%	32,342	32,900	557	101.7%
研究開発費 Research and development	275	275	△ 0	100.0%	370	400	29	108.0%
管理費、その他 Other, net	9,158	9,124	△ 34	99.6%	12,023	12,200	176	101.5%
販売費及び一般管理費 SG&A expenses	41,108	41,397	289	100.7%	54,589	55,600	1,010	101.9%
営業利益(△:損失) Operating income(Δ:loss)	6,698	6,683	△ 15	99.8%	5,569	6,100	530	109.5%
営業外収益 Non-operating income	1,315	749	△ 566	56.9%	1,369	750	△ 619	54.8%
営業外費用 Non-operating expenses	187	245	57	130.9%	256	250	△ 6	97.5%
経常利益(△:損失) Ordinary income(Δ:loss)	7,827	7,187	△ 640	91.8%	6,681	6,600	△ 81	98.8%
特別利益 Extraordinary income	4,701	2	△ 4,698	0.1%	4,711	50	△ 4,661	1.1%
特別損失 Extraordinary loss	80	42	△ 37	52.6%	150	150	△ 0	99.5%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	12,448	7,147	△ 5,300	57.4%	11,243	6,500	△ 4,743	57.8%
法人税、住民税及び事業税 Current income taxes	3,138	2,097	△ 1,040	66.8%	2,887	2,000	△ 910	68.7%
法人税等調整額 Deferred income taxes	259	35	△ 223	13.9%	22			
四半期純利益(△:損失) Net income(Δ:loss)	9,051	5,014	△ 4,036	55.4%	8,332	4,500	△ 3,832	54.0%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	–	–	–	–	–	–	–	–
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	9,051	5,014	△ 4,036	55.4%	8,332	4,500	△ 3,832	54.0%
設備投資額(有形・無形) Capital expenditures	1,348	1,019	△ 328	75.7%	2,696	3,700	1,003	137.2%
減価償却費(有形・無形) Depreciation and Amortization	1,626	1,647	20	101.2%	2,225	2,300	74	103.3%

(注)平成30年3月期第3四半期累計の実績において、「焼酎」売上高の一部を「ソフトアルコール飲料」に組み替えております。

3. 宝酒造インターナショナルグループ :Takara Shuzo International Group

要約損益計算書 Statements of Income (Summary)

→[参考:通期 Reference:Full year]

(百万円 Millions of Yen)

	平成30年3月期 第3四半期累計	平成31年3月期 第3四半期累計 Apr. 1, 2018 - Dec. 31, 2018			平成30年3月期 通期	平成31年3月期 通期 Apr. 1, 2018 - Mar. 31, 2019		
	実績(a) FY2018(1Q-3Q) Actual (a)	実績(b) FY2019(1Q-3Q) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)	実績(c) FY2018 Actual (c)	11/6予想(d) FY2019 Forecast announced Nov. 2018 (d)	増減(d-c) Change (d-c)	比(d/c) YOY% (d/c)
海外酒類事業 Overseas Alcoholic beverages business	7,424	7,616	192	102.6%	10,483	10,800	316	103.0%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	45,231	50,591	5,360	111.9%	62,079	69,500	7,420	112.0%
その他 Other	33	48	15	145.2%	49	100	50	201.7%
連結消去 Elimination	△ 1,324	△ 1,413	△ 88	—	△ 1,895	△ 2,400	△ 504	—
売上高 Net sales	51,364	56,843	5,478	110.7%	70,717	78,000	7,282	110.3%
売上原価 Cost of sales	36,170	40,196	4,025	111.1%	49,843	54,700	4,856	109.7%
売上総利益 Gross profit	15,194	16,647	1,452	109.6%	20,874	23,300	2,425	111.6%
運送費、保管料 Transportation and storage	1,405	1,623	217	115.5%	1,921	2,500	578	130.1%
広告宣伝費 Advertising	61	79	17	128.5%	89	100	10	111.5%
販売促進費 Sales promotion	420	482	62	114.8%	640	700	59	109.3%
研究開発費 Research and development	—	—	—	—	—	—	—	—
管理費、その他 Other, net	10,100	11,231	1,131	111.2%	13,829	15,100	1,270	109.2%
販売費及び一般管理費 SG&A expenses	11,988	13,416	1,428	111.9%	16,480	18,400	1,919	111.6%
海外酒類事業 Overseas Alcoholic beverages business	1,421	1,344	△ 76	94.6%	1,972	1,900	△ 72	96.3%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	2,733	2,939	206	107.5%	3,735	4,600	864	123.1%
その他 Other	△ 594	△ 707	△ 112	—	△ 828	△ 1,100	△ 271	—
連結消去 Elimination	△ 354	△ 347	7	—	△ 485	△ 500	△ 14	—
営業利益(△:損失) Operating income(Δ:loss)	3,206	3,230	24	100.8%	4,393	4,900	506	111.5%
営業外収益 Non-operating income	192	168	△ 23	87.7%	204	350	145	170.8%
営業外費用 Non-operating expenses	212	287	74	135.2%	268	250	△ 18	93.3%
経常利益(△:損失) Ordinary income(Δ:loss)	3,185	3,111	△ 74	97.7%	4,330	5,000	669	115.5%
特別利益 Extraordinary income	4	0	△ 3	7.6%	4	50	45	1120.2%
特別損失 Extraordinary loss	2	10	8	477.5%	18	50	31	269.6%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	3,187	3,101	△ 86	97.3%	4,316	5,000	683	115.8%
法人税、住民税及び事業税 Current income taxes	1,323	916	△ 407	69.2%	1,913	1,600	96	106.4%
法人税等調整額 Deferred income taxes	△ 36	11	47	—	△ 409			
四半期純利益(△:損失) Net income(Δ:loss)	1,900	2,173	272	114.3%	2,812	3,400	587	120.9%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	386	333	△ 52	86.3%	581	500	△ 81	86.0%
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	1,514	1,840	325	121.5%	2,230	2,900	669	130.0%
設備投資額(有形・無形) Capital expenditures	1,130	832	△ 297	73.7%	1,677	3,570	1,892	212.8%
減価償却費(有形・無形) Depreciation and Amortization	698	748	49	107.1%	938	1,000	61	106.5%
のれん償却額 Amortization of goodwill	261	272	11	104.4%	353	360	6	101.8%

4. タカラバイオグループ :Takara Bio Group

要約損益計算書 Statements of Income (Summary)

→[参考:通期 Reference:Full year]

(百万円 Millions of Yen)

	平成30年3月期 第3四半期累計	平成31年3月期 第3四半期累計 Apr. 1, 2018 - Dec. 31, 2018			平成30年3月期 通期	平成31年3月期 通期 Apr. 1, 2018 - Mar. 31, 2019		
	実績(a) FY2018(1Q-3Q) Actual (a)	実績(b) FY2019(1Q-3Q) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)	実績(c) FY2018 Actual (c)	1/30予想(d) FY2019 Forecast announced Jan. 2019 (d)	増減(d-c) Change (d-c)	比(d/c) YOY% (d/c)
研究用試薬 Research reagents	15,663	17,093	1,430	109.1%	22,207	23,703	1,495	106.7%
理化学機器 Scientific instruments	1,890	1,907	17	100.9%	2,635	2,587	△ 47	98.2%
受託・その他 Contracted service and other	2,852	2,983	131	104.6%	4,725	5,190	464	109.8%
バイオ産業支援 計 Bioindustry	20,405	21,984	1,578	107.7%	29,568	31,481	1,912	106.5%
遺伝子医療 Gene Therapy	500	2,304	1,804	460.9%	500	2,438	1,938	487.8%
医食品バイオ AgriBio	1,740	1,599	△ 141	91.9%	2,243	1,879	△ 364	83.7%
売上高 Net sales	22,646	25,888	3,242	114.3%	32,312	35,800	3,487	110.8%
売上原価 Cost of sales	9,879	10,947	1,068	110.8%	13,657	14,934	1,277	109.4%
売上総利益 Gross profit	12,766	14,940	2,174	117.0%	18,655	20,865	2,209	111.8%
運送費、保管料 Transportation and storage	469	514	45	109.6%	643	692	49	107.7%
広告宣伝費 Advertising	59	38	△ 20	65.2%	83	56	△ 26	67.9%
販売促進費 Sales promotion	581	544	△ 37	93.6%	729	713	△ 15	97.9%
研究開発費 Research and development	3,417	3,164	△ 252	92.6%	4,653	4,472	△ 181	96.1%
管理費、その他 Other, net	6,629	7,244	615	109.3%	8,990	9,729	739	108.2%
販売費及び一般管理費 SG&A expenses	11,157	11,507	350	103.1%	15,099	15,665	565	103.7%
バイオ産業支援 Bioindustry	3,696	4,138	442	112.0%	6,683	6,959	276	104.1%
遺伝子医療 Gene Therapy	△ 802	885	1,688	—	△ 1,322	398	1,721	—
医食品バイオ AgriBio	110	△ 3	△ 114	—	107	26	△ 80	24.6%
共通 Eliminations/Corporate	△ 1,395	△ 1,587	△ 192	—	△ 1,912	△ 2,185	△ 272	—
営業利益(△:損失) Operating income(Δ:loss)	1,608	3,432	1,823	213.4%	3,555	5,200	1,644	146.2%
営業外収益 Non-operating income	236	201	△ 34	85.3%	402	297	△ 104	74.1%
営業外費用 Non-operating expenses	82	84	2	102.7%	96	97	1	102.0%
経常利益(△:損失) Ordinary income(Δ:loss)	1,762	3,549	1,786	201.4%	3,861	5,400	1,538	139.8%
特別利益 Extraordinary income	0	55	54	—	0	125	125	—
特別損失 Extraordinary loss	20	900	880	—	501	912	410	181.9%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	1,742	2,703	961	155.2%	3,361	4,613	1,252	137.3%
法人税、住民税及び事業税 Current income taxes	555	1,107	551	199.4%	1,155	1,441	418	140.9%
法人税等調整額 Deferred income taxes	119	△ 494	△ 614	—	△ 132			
四半期純利益(△:損失) Net income(Δ:loss)	1,067	2,091	1,024	196.0%	2,338	3,172	833	135.7%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	△ 1	3	4	—	3	22	19	723.2%
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	1,068	2,088	1,019	195.4%	2,335	3,150	814	134.9%
設備投資額(有形・無形) Capital expenditures	910	3,124	2,214	343.2%	1,539	7,103	5,564	461.4%
減価償却費(有形・無形) Depreciation and Amortization	1,896	2,014	117	106.2%	2,568	2,703	134	105.2%
のれん償却額 Amortization of goodwill	364	374	9	102.7%	489	502	13	102.7%

5. 6年間の財務サマリー(グループ別) :Six-Year Financial Summary by Business Group

宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

(百万円 :Millions of Yen)

		平成26年3月期 第3四半期 FY2014 (1Q-3Q)	平成27年3月期 第3四半期 FY2015 (1Q-3Q)	平成28年3月期 第3四半期 FY2016 (1Q-3Q)	平成29年3月期 第3四半期 FY2017 (1Q-3Q)	平成30年3月期 第3四半期 FY2018 (1Q-3Q)	平成31年3月期 第3四半期 FY2019 (1Q-3Q)	前期対比 Change from FY2018(1Q-3Q) 増減 Change	比 YOY%
売上高	Net sales	159,519	166,054	170,250	172,218	204,266	210,622	6,356	103.1%
売上原価	Cost of sales	98,027	100,975	102,349	101,336	124,486	127,706	3,219	102.6%
(売上高原価率)	(Ratio to Net sales)	61.5%	60.8%	60.1%	58.8%	60.9%	60.6%	-0.3pt	–
売上総利益	Gross profit	61,491	65,078	67,901	70,881	79,779	82,915	3,136	103.9%
販売費及び一般管理費	SG&A expenses	52,599	54,497	57,809	58,139	66,175	67,900	1,724	102.6%
(売上高販管費率)	(Ratio to Net sales)	33.0%	32.8%	34.0%	33.8%	32.4%	32.2%	-0.2pt	–
営業利益(△:損失)	Operating income(Δ:loss)	8,891	10,580	10,091	12,741	13,604	15,015	1,411	110.4%
(売上高営業利益率)	(Ratio to Net Sales)	5.6%	6.4%	5.9%	7.4%	6.7%	7.1%	+0.5pt	–
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	24,214	23,957	24,561	25,020	24,840	25,131	291	101.2%
(売上高販促費率)	(Ratio to Net sales)	15.2%	14.4%	14.4%	14.5%	12.2%	11.9%	-0.2pt	–
研究開発費	R&D expenses	2,412	2,485	3,363	3,155	3,726	3,444	△ 281	92.4%
(売上高研究開発費率)	(Ratio to Net sales)	1.5%	1.5%	2.0%	1.8%	1.8%	1.6%	-0.2pt	–
設備投資額(有形・無形)	Capital expenditures	5,324	6,904	3,768	3,749	3,738	5,156	1,417	137.9%
減価償却費(有形・無形)	Depreciation and Amortization	3,111	3,358	3,820	3,753	4,767	4,813	46	101.0%
のれん償却額	Amortization of goodwill	265	350	404	349	625	646	21	103.4%

宝酒造 :Takara Shuzo Co., Ltd.

(百万円 :Millions of Yen)

		平成26年3月期 第3四半期 FY2014 (1Q-3Q)	平成27年3月期 第3四半期 FY2015 (1Q-3Q)	平成28年3月期 第3四半期 FY2016 (1Q-3Q)	平成29年3月期 第3四半期 FY2017 (1Q-3Q)	平成30年3月期 第3四半期 FY2018 (1Q-3Q)	平成31年3月期 第3四半期 FY2019 (1Q-3Q)	前期対比 Change from FY2018(1Q-3Q) 増減 Change	比 YOY%
売上高	Net sales	–	–	–	116,025	117,845	119,001	1,155	101.0%
売上原価	Cost of sales	–	–	–	68,731	70,038	70,919	881	101.3%
(売上高原価率)	(Ratio to Net sales)				59.2%	59.4%	59.6%	+0.2pt	–
売上総利益	Gross profit				47,293	47,806	48,081	274	100.6%
販売費及び一般管理費	SG&A expenses				41,112	41,108	41,397	289	100.7%
(売上高販管費率)	(Ratio to Net sales)				35.4%	34.9%	34.8%	-0.1pt	–
営業利益(△:損失)	Operating income(Δ:loss)				6,181	6,698	6,683	△ 15	99.8%
(売上高営業利益率)	(Ratio to Net sales)				5.3%	5.7%	5.6%	-0.1pt	–
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.				24,054	23,864	24,148	284	101.2%
(売上高販促費率)	(Ratio to Net sales)				20.7%	20.3%	20.3%	+0.0pt	–
設備投資額(有形・無形)	Capital expenditures	–	–	–	1,094	1,348	1,019	△ 328	75.7%
減価償却費(有形・無形)	Depreciation and Amortization	–	–	–	1,607	1,626	1,647	20	101.2%

平成30年3月期からの新セグメントです。
This is a new segment from the fiscal year ended March 2018.

宝酒造インターナショナルグループ :Takara Shuzo International Group

(百万円 :Millions of Yen)

		平成26年3月期 第3四半期 FY2014 (1Q-3Q)	平成27年3月期 第3四半期 FY2015 (1Q-3Q)	平成28年3月期 第3四半期 FY2016 (1Q-3Q)	平成29年3月期 第3四半期 FY2017 (1Q-3Q)	平成30年3月期 第3四半期 FY2018 (1Q-3Q)	平成31年3月期 第3四半期 FY2019 (1Q-3Q)	前期対比 Change from FY2018(1Q-3Q) 増減 Change	比 YOY%
売上高	Net sales	–	–	–	22,021	51,364	56,843	5,478	110.7%
売上原価	Cost of sales	–	–	–	14,801	36,170	40,196	4,025	111.1%
(売上高原価率)	(Ratio to Net sales)	–	–	–	67.2%	70.4%	70.7%	+0.3pt	–
売上総利益	Gross profit				7,220	15,194	16,647	1,452	109.6%
販売費及び一般管理費	SG&A expenses				5,264	11,988	13,416	1,428	111.9%
(売上高販管費率)	(Ratio to Net sales)				23.9%	23.3%	23.6%	+0.3pt	–
営業利益(△:損失)	Operating income(Δ:loss)				1,955	3,206	3,230	24	100.8%
(売上高営業利益率)	(Ratio to Net sales)				8.9%	6.2%	5.7%	-0.6pt	–
のれん償却後営業利益(△:損失)	Operating income after amortization of goodwill				1,727	2,944	2,957	12	100.4%
(のれん償却後営業利益率)	(Ratio to Net sales)				7.8%	5.7%	5.2%	-0.5pt	–
設備投資額(有形・無形)	Capital expenditures	–	–	–	404	1,130	832	△ 297	73.7%
減価償却費(有形・無形)	Depreciation and Amortization	–	–	–	417	698	748	49	107.1%
のれん償却額	Amortization of goodwill	–	–	–	227	261	272	11	104.4%

平成30年3月期からの新セグメントです。
This is a new segment from the fiscal year ended March 2018.

タカラバイオグループ :Takara Bio Group

(百万円 :Millions of Yen)

		平成26年3月期 第3四半期 FY2014 (1Q-3Q)	平成27年3月期 第3四半期 FY2015 (1Q-3Q)	平成28年3月期 第3四半期 FY2016 (1Q-3Q)	平成29年3月期 第3四半期 FY2017 (1Q-3Q)	平成30年3月期 第3四半期 FY2018 (1Q-3Q)	平成31年3月期 第3四半期 FY2019 (1Q-3Q)	前期対比 Change from FY2018(1Q-3Q) 増減 Change	比 YOY%
売上高	Net sales	16,167	17,293	20,706	20,645	22,646	25,888	3,242	114.3%
売上原価	Cost of sales	7,500	7,839	9,199	8,106	9,879	10,947	1,068	110.8%
(売上高原価率)	(Ratio to Net sales)	46.4%	45.3%	44.4%	39.3%	43.6%	42.3%	-1.3pt	–
売上総利益	Gross profit	8,666	9,453	11,507	12,538	12,766	14,940	2,174	117.0%
販売費及び一般管理費	SG&A expenses	7,758	8,190	10,062	9,813	11,157	11,507	350	103.1%
(売上高販管費率)	(Ratio to Net sales)	48.0%	47.4%	48.6%	47.5%	49.3%	44.5%	-4.8pt	–
営業利益(△:損失)	Operating income(Δ:loss)	908	1,263	1,444	2,724	1,608	3,432	1,823	213.4%
(売上高営業利益率)	(Ratio to Net sales)	5.6%	7.3%	7.0%	13.2%	7.1%	13.3%	+6.2pt	–
研究開発費	R&D expenses	2,154	2,225	3,118	2,870	3,417	3,164	△ 252	92.6%
(売上高研究開発費率)	(Ratio to Net sales)	13.3%	12.9%	15.1%	13.9%	15.1%	12.2%	-2.9pt	–
設備投資額(有形・無形)	Capital expenditures	3,230	3,380	1,850	1,200	910	3,124	2,214	343.2%
減価償却費(有形・無形)	Depreciation and Amortization	849	956	1,247	1,276	1,896	2,014	117	106.2%
のれん償却額	Amortization of goodwill	100	92	135	121	364	374	9	102.7%

(参考)宝酒造グループ :Reference Data for the Takara Shuzo Group

(百万円 :Millions of Yen)

		平成26年3月期 第3四半期 FY2014 (1Q-3Q)	平成27年3月期 第3四半期 FY2015 (1Q-3Q)	平成28年3月期 第3四半期 FY2016 (1Q-3Q)	平成29年3月期 第3四半期 FY2017 (1Q-3Q)	平成30年3月期 第3四半期 FY2018 (1Q-3Q)	平成31年3月期 第3四半期 FY2019 (1Q-3Q)	前期対比 Change from FY2018(1Q-3Q) 増減 Change	比 YOY%
売上高	Net sales	140,850	146,178	146,859	148,818	–	–	–	–
売上原価	Cost of sales	89,404	91,977	91,986	92,152				–
売上総利益	Gross profit	51,446	54,200	54,872	56,666				–
販売費及び一般管理費	SG&A expenses	44,404	45,764	46,787	47,252				–
営業利益(△:損失)	Operating income(Δ:loss)	7,041	8,435	8,085	9,413				–
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	23,422	23,258	23,759	24,287				–
設備投資額(有形・無形)	Capital expenditures	1,969	3,463	1,783	1,675				–
減価償却費(有形・無形)	Depreciation and Amortization	2,143	2,294	2,396	2,298				–
のれん償却額	Amortization of goodwill	164	257	268	227	–	–	–	–

平成29年3月期までの旧セグメントです。
This is an old segment until the fiscal year ended March 2017.

6. 平成31年3月期第3四半期 参考資料 :Reference Data for the Third Quarter Ended December 31, 2018

① 為替前提及び売上高に対する為替レート変動の影響 :Exchange rates and effect of change in exchange rates on net sales

◆為替前提(海外子会社P/L換算用) :Exchange rates for the income statement of oversea subsidiaries

(円 : Yen)

	平成30年3月期 第3四半期累計	平成31年3月期 第3四半期累計 Apr. 1, 2018 - Dec. 31, 2018	
	実績(a) FY2018(1Q-3Q) Actual (a)	実績(b) FY2019(1Q-3Q) Actual (b)	前期差 Change(c-a)
米ドル : US dollar	111.89	109.61	△ 2.28
ポンド: Pound	142.64	148.11	5.47
ユーロ: Euro	124.58	130.87	6.29
人民元: Yuan	16.47	16.84	0.37
100ウォン: 100 Won	9.84	10.05	0.21
インドルピー: Rupee	1.72	1.64	△ 0.08
ｽｳｪｰﾃﾞﾝｸﾛｰﾅ :Sweden krona	13.00	12.79	△ 0.21
ｼﾝｶﾞﾎﾟｰﾙﾄﾞﾙ :Singapore dollar	80.53	81.78	1.25
ｵｰｽﾄﾗﾘｱﾄﾞﾙ :Australian dollar	85.73	83.06	△ 2.67

◆売上高に対する為替レート変動の影響額 :Effect of change in exchange rates on net sales

(百万円 :Millions of Yen)

	対前期 Change from FY2018(1Q-3Q)
宝ホールディングス 計 Net sales of Takara Holdings Inc. -Consolidated-	302
うち宝酒造ｲﾝﾀｰﾅｼｮﾅﾙｸﾞﾙｰﾌﾟ Net sales of Takara Shuzo International Group	238
海外酒類事業 Overseas Alcoholic beverages business	△ 7
海外日本食材卸事業 Japanese food wholesale business in overseas markets	226
その他 Other	―
連結消去 Elimination	19
うちタカラバイオグループ Net sales of Takara Bio Group	64
研究用試薬 Research reagents	59
理化学機器 Scientific instruments	0
受託・その他 Contracted service and other	3
バイオ産業支援 計 Bioindustry	64
遺伝子医療 Gene Therapy	―
医食品バイオ AgriBio	―

② 海外売上高比率 :Overseas sales ratio

(百万円 :Millions of Yen)

	平成30年3月期第3四半期 実績 FY2018(1Q-3Q) Actual			平成31年3月期第3四半期 実績 FY2019(1Q-3Q) Actual		
	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio
宝酒造 Takara Shuzo Co., Ltd.	117,845	―	―	119,001	―	―
宝酒造ｲﾝﾀｰﾅｼｮﾅﾙｸﾞﾙｰﾌﾟ Takara Shuzo International Group	51,364	51,092	99.5%	56,843	56,582	99.5%
タカラバイオグループ Takara Bio Group	22,646	12,972	57.3%	25,888	14,586	56.3%
その他および調整額 Other / Adjustment	12,409	―	―	8,889	―	―
宝ホールディングス(連結) Takara Holdings Inc. -Consolidated-	204,266	64,064	31.4%	210,622	71,168	33.8%

③ 海外主要子会社の業績 :Financial Forecast of major overseas subsidiaries

		平成30年3月期第3四半期 実績 FY2018(1Q-3Q) Actual		平成31年3月期第3四半期 実績 FY2019(1Q-3Q) Actual	
		売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
米国宝酒造	千 US ドル :Thousands of US dollar	23,931	3,931	24,470	2,048
Takara Sake USA Inc.	百 万 円 :Millions of Yen	2,677	439	2,682	224
宝酒造食品	千 元 :Thousands of Yuan	35,666	662	38,352	2,314
Takara Shuzo Foods Co.,Ltd.	百 万 円 :Millions of Yen	587	10	645	38
トマーチン	千 ポ ン ド :Thousands of Pound	13,575	3,171	12,811	3,405
The Tomatin Distillery Co.,Ltd.	百 万 円 :Millions of Yen	1,936	452	1,897	504
ｴｲｼﾞ・ｲﾝﾀｰﾅｼｮﾅﾙ	千 US ドル :Thousands of US dollar	15,222	6,107	16,209	6,723
AGE INTERNATIONAL,INC.	百 万 円 :Millions of Yen	1,703	683	1,776	736
フーデックスグループ	千 ユ ー ロ :Thousands of Euro	111,093	13,094	118,161	12,661
FOODEX Group	百 万 円 :Millions of Yen	13,839	1,631	15,463	1,656
タザキフーズ	千 ポ ン ド :Thousands of Pound	27,127	547	29,443	2,049
TAZAKI FOODS LTD.	百 万 円 :Millions of Yen	3,869	78	4,360	303
ミューチャルトレーディング	千 US ドル :Thousands of US dollar	221,001	9,149	250,196	9,218
Mutual Trading Co., Inc.	百 万 円 :Millions of Yen	24,727	1,023	27,424	1,010
ニッポンフード	千 AUS ドル :Thousands of Australian dollar	32,592	6	40,243	Δ 373
Nippon Food Supplies Company Pty Ltd	百 万 円 :Millions of Yen	2,794	0	3,342	Δ 31
ﾀｶﾗﾊﾞｲｵﾖｰﾛｯﾊﾟS.A.S.	千 ユ ー ロ :Thousands of Euro	14,683	913	16,474	1,674
Takara Bio Europe S.A.S.	百 万 円 :Millions of Yen	1,829	113	2,156	219
ﾀｶﾗﾊﾞｲｵﾖｰﾛｯﾊﾟAB	千 SEK :Thousands of Sweden Krona	28,813	Δ 2,153	26,801	Δ 7,227
Takara Bio Europe AB	百 万 円 :Millions of Yen	374	Δ 27	342	Δ 92
宝生物工程(大連)	千 元 :Thousands of Yuan	153,028	37,307	171,117	39,327
Takara Biotechnology (Dalian) Co.,Ltd.	百 万 円 :Millions of Yen	2,520	614	2,881	662
宝日医生物技術(北京)	千 元 :Thousands of Yuan	235,122	30,950	263,935	47,111
Takara Biomedical Technology(Beijing) Co., Ltd.	百 万 円 :Millions of Yen	3,872	509	4,444	793
ﾀｶﾗｺﾘｱﾊﾞｲｵﾒﾃﾞｨｶﾙ	百 万 ウ ォ ン :Millions of Won	7,615	1,123	7,558	1,233
Takara Korea Biomedical Inc.	百 万 円 :Millions of Yen	749	110	759	123
タカラバイオDSSインド	千 ｲﾝﾄﾞﾙﾋﾟｰ :Thousands of Rupee	137,520	Δ 8,493	146,232	2,829
DSS Takara Bio India Private Limited	百 万 円 :Millions of Yen	236	Δ 14	239	4
タカラバイオUSA	千 US ドル :Thousands of US dollar	67,153	4,675	73,958	8,655
Takara Bio USA, Inc.	百 万 円 :Millions of Yen	7,513	523	8,106	948

④ 宝酒造 売上総利益増減要因 :Factors of change in Gross profit of Takara Shuzo Co., Ltd.

(百万円 :Millions of Yen)

	対前期増減 Change from FY2018(1Q-3Q)		
	増減計 Total Change	数量差 Change in quantities	単価差 Change in unit price
売上総利益 計 Gross profit	+274	+76	+197
(主な内訳)			
焼酎 Shochu	Δ 389	Δ 620	+231
清酒 Sake	Δ 400	Δ 378	Δ 22
ｿﾌﾄｱﾙｺｰﾙ飲料 Light-alcohol refreshers	+1,382	+1,189	+193
本みりん Hon Mirin	Δ 184	Δ 181	Δ 3
(参考)原価コストダウン Reference :Cost reduction	+25	※上記数量差および単価差に含む *Included in changes above	

※利益の増加要因を「+」、減少要因を「△」で表示

*An increasing factor and a decreasing factor on profit are shown 「+」 and 「△」, respectively

⑤ 宝ホールディングス(連結)要約損益計算書(p.1)における「その他」の内訳

Breakdown of "Other" segment in the Consolidated Statemnets of Income of Takara Holdings Inc. (Summary) (p.1)

	平成30年3月期第3四半期 実績 FY2018(1Q-3Q) Actual		平成31年3月期第3四半期 実績 FY2019(1Q-3Q) Actual	
	売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
物流事業 Transportation	13,579	872	10,876	504
宝ヘルスケア Takara Healthcare	1,216	79	998	32
宝ホールディングス(不動産事業) Takara Holdings (Real estate business)	350	302	402	330
その他 Other	13,944	861	13,315	783
「その他」計 Total "Other"	29,090	2,115	25,593	1,651